Omid Omidvar, MD
Neurology · Los Alamitos, CANPI 1184678583
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,529 of the $19,435 with a category attached, or 79.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations.
Across 701 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AbbVie$2K
- Abbott$2K
- Sage Therapeutics, LLC$2K
- AstraZeneca$873
- Biogen$872
- plus $10K from 54 others
Across 289 payments — averaging $8581.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$834K
- Eli Lilly$431K
- Genentech, Inc.$211K
- Sanofi$208K
- Merck$185K
- F. Hoffmann-la Roche AG$99K
- plus $511K from 16 others
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$410%
- Travel & lodging$3,28417%
- Food & beverage$15,52980%
- Education$2801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$1,423
- VNS Therapy$565
- TYSABRI$300
- GENERAL DBS$178
- MAYZENT$125
- VYEPTI$125
- ULTOMIRIS$122
- VALTOCO$118
- Zilbrysq$105
How this compares
$19,435 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $182,805 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $88,062 |
| NuplazidPimavanserin Tartrate | 16 | $76,559 |
| NeuproRotigotine | 45 | $51,281 |
| RytaryCarbidopa/Levodopa | 31 | $44,940 |
| NourianzIstradefylline | 13 | $29,192 |
| TrintellixVortioxetine Hydrobromide | 30 | $24,460 |
| BelsomraSuvorexant | 52 | $23,845 |
| LeqembiLecanemab-Irmb | 18 | $22,441 |
| BriviactBrivaracetam | 16 | $21,908 |
| Rasagiline Mesylate | 104 | $20,763 |
| Rivastigmine | 62 | $17,381 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $11,983 |
| OngentysOpicapone | 13 | $10,438 |
| MyrbetriqMirabegron | 17 | $9,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix | $26 | $112,52243 claims |
| Acadia Pharmaceuticals IncNuplazid | $753 | $76,55916 claims |
| UCB, Inc.Neupro, Briviact | $622 | $73,18961 claims |
| Eisai Inc.Leqembi, Dayvigo | $455 | $31,33537 claims |
| Kyowa Kirin, Inc.Nourianz | $180 | $29,19213 claims |
| Neurocrine Biosciences, Inc.Ongentys | $630 | $10,43813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.
Other neurology in Los Alamitos
- Nirav PatelLos Alamitos$755K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.